WO1996034953A2 - Variants de cd16-ii - Google Patents

Variants de cd16-ii Download PDF

Info

Publication number
WO1996034953A2
WO1996034953A2 PCT/IB1996/000590 IB9600590W WO9634953A2 WO 1996034953 A2 WO1996034953 A2 WO 1996034953A2 IB 9600590 W IB9600590 W IB 9600590W WO 9634953 A2 WO9634953 A2 WO 9634953A2
Authority
WO
WIPO (PCT)
Prior art keywords
leu
ser
val
thr
lys
Prior art date
Application number
PCT/IB1996/000590
Other languages
English (en)
Other versions
WO1996034953A3 (fr
Inventor
Shun Luo
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Priority to JP8533162A priority Critical patent/JPH11511649A/ja
Priority to CA002219988A priority patent/CA2219988C/fr
Priority to EP96916264A priority patent/EP0954576A2/fr
Priority to KR1019970707811A priority patent/KR100464923B1/ko
Priority to AU59083/96A priority patent/AU697991B2/en
Publication of WO1996034953A2 publication Critical patent/WO1996034953A2/fr
Publication of WO1996034953A3 publication Critical patent/WO1996034953A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to human CD16-II protein variants, DNA sequences coding for them, their use in therapy and/or in diagnosis of autoimmune diseases and inflammatory illnesses, as well as pharmaceutical compositions comprising them.
  • CD16 also called Fc receptor-III (FC7R-III)
  • FC7R-III Fc receptor-III
  • CD16 plays an important role in mediating autoimmunity and inflammatory responses.
  • ADCC antibody-dependent cell mediated cellular cytotoxicity
  • CD16 is present in human serum and other body fluids and is elevated at sites of inflammation (see Fleit et al., Blood, 79, (10) , 1992, pp. 2721-8) .
  • CD16-I and CD16-II there are at least two isoforms of human CD16, type 1 and type 2, that can be designated as CD16-I and CD16-II, respectively.
  • These two isoforms of CD16 are human CD16, type 1 and type 2, that can be designated as CD16-I and CD16-II, respectively.
  • These two isoforms of CD16 are encoded by two separate but related genes, NA1 and NA2.
  • CD16-I and CD16-II are distinct in both structure and cellular expression.
  • CD16-I is expressed predominantly on the surface of neutrophils and monocytes, whereas CD16-II is expressed predominantly on the surface of macrophages, natural killer cells and large granular lymphocytes (NK/LGL) .
  • these two types of CD-16 are associated with the cell surface via two distinct mechanisms: CD16 type I is associated with the cell surface by glycosyl-phosphotidylinositol (GPI) linkage; whereas CD16 type II is anchored on the membrane with about 20 extra amino acids.
  • GPI glycosyl-phosphotidylinositol
  • the N-terminus of the mature CD16 has been investigated and the methionine residue at position 18 was identified as the N-terminal residue of the mature protein.
  • the initial translation product contains a 17-amino acid signal peptide.
  • the transmembrane region of CD16-II is shown to be from amino acid 209 to 229, whereas CD16-I is reported lacking transmembranal and cytoplasmic domains.
  • CD16-I For human CD16-I, a polymorphism has been reported previously, as is evident from Figure 1, whereas only one alternative nucleic acid sequence encoding CD16-II has been published until now (Ravetch et al., J. Exp. Med. , 170, 1989, pp. 481-97).
  • CD16-I-NA1 exhibited a 21-25% higher IgGl mediated phagocytosis than CD16-I-NA2.
  • European Patent Application EP 343 950 generally discloses soluble and membrane-bound human Fc R-III polypeptides as well as nucleic acids capable of encoding the same.
  • sequence of a CD16-I variant and the sequence of CD16-II are shown in the Figures. This patent application further discloses various utilities for these polypeptides.
  • the present invention is based on the discovery of new human CD16-II variant clones. They have been isolated by using an RT-PCR (Reverse Transcriptase-Poly erase Chain Reaction) -based strategy using designed isoform-specific oligonucleotide primers. In particular, from a pooled human lung RNA extract, CD16-II has been amplified via RT-PCR. These CD16-II variants provide a therapeutic intervening approach and/or a diagnostic tool for autoimmune and inflammatory diseases. As they are natural variants of the CD16-II sequence previously published, the polypeptides of the present invention can be used for any of the utilities previously disclosed for CD16-II. All of the utilities for CD16-II made evident from any of the publications disclosed herein are hereby incorporated herein by reference, and particularly those in European application 343,950.
  • the main object of the present invention are the polypeptides comprising respectively the SEQ ID NO: 1, 2, 3 and 4. - 4 -
  • nucleotide sequences substantially the same includes all other nucleic acid sequences which, by virtue of the degeneracy of the genetic code, also code for the given amino acid sequences.
  • Preparation of an alternative nucleotide sequence encoding the same polypeptide but differing from the natural sequence due to changes permitted by the known degeneracy of the genetic code can be achieved by site-specific mutagenesis of DNA that encodes an earlier prepared variant or a nonvariant version of the polypeptide of the present invention.
  • Site-specific mutagenesis allows the production of variants through the use of specific oligonucleotide sequences that encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed.
  • a primer typically of about 20 to 25 nucleotides in length is preferred, with about 5 to 10 complementing nucleotides on each side of the sequence being altered.
  • the technique of site-specific mutagenesis is well known in the art, as exemplified by publications- such as Adelman et al., DNA, 2:183 (1983) , the disclosure of which is incorporated herein by reference.
  • the site-specific mutagenesis technique typically employs a phage vector that exists in both a single-stranded and double-stranded form.
  • Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage, for example, as disclosed by
  • plasmid vectors that contain a single-stranded phage origin of replication may be employed to obtain single-stranded DNA.
  • site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector that includes within its sequence a DNA sequence that encodes the relevant protein.
  • An oligonucleotide primer bearing the desired mutated sequence is prepared synthetically by automated DNA/oligonucleotide synthesis. This primer is then annealed with the single-stranded protein-sequence-containing vector, and subjected to DNA-polymerizing enzymes such as E .
  • the proteins of the invention are useful in the therapy and/or diagnosis of autoimmune diseases and inflammatory illnesses. Therefore, in a further aspect, the present invention provides the use of each protein of the invention in the manufacture of a medicament for the treatment of autoimmune diseases and inflammatory illnesses.
  • the medicament is preferably presented in the form of a pharmaceutical composition comprising one of the proteins of the invention together with one or more pharmaceutically acceptable carriers and/or excipients.
  • Such pharmaceutical compositions form yet a further aspect of the present invention.
  • Figure 1 shows the sequence alignment of various CD16 variants, including those of the present invention.
  • the alignment has been done by using the PC/Gene Software.
  • the symbol “*” shows that a position in the alignment is "perfectly conserved”.
  • the symbol “.” shows that a position is "well conserved”.
  • a blank space shows that a position is not conserved.
  • CD16I_1 is the human CD16-I aa sequence reported in Simmons et al., Nature, 333, pp. 568-570, 1988 (SEQ ID NO:5).
  • CD16I_2 is the human CD16-I aa sequence reported in Peltz et al., PNAS USA. 86, pp. 1013-7, 1989 (SEQ ID NO:6) .
  • CD16I_3 is the human CD16-I aa sequence reported in Scallon et al., PNAS USA, 86, pp. 5079-83, 1989 (SEQ ID NO:7) .
  • CD16I_4 is the human CD16-I aa sequence reported in Lanier, Science. 246, pp. 1611-3, 1989 (SEQ ID NO:8) .
  • FCG3 human is the CD16-II aa sequence reported in Ravetch et al., J. Exp. Med.. 170, pp. 481-7, 1989 (SEQ ID NO:9) .
  • CD16II_1 is the human CD16-I aa sequence reported in Scallon et al., PNAS USA, 86, pp. 5079-83, 1989 (SEQ ID NO:7) .
  • CD16I_4 is the human CD16-I aa sequence reported in Lanier, Science. 246, pp. 1611-3, 1989 (SEQ ID NO:8) .
  • CD16II_2 is the CD16-II aa sequences of the proteins of the present invention respectively SEQ ID NO: 1, 2, 3 and 4.
  • Figure 2 illustrates the reverse transcriptase based polymerase chain reaction (RT-PCR) amplification of human CD16.
  • Panel A shows the isoform-specific oligonucleotide PCR primers.
  • the primers on the line marked "Type I” (CD16pl (nucleotides 7- 21 of SEQ ID NO: 17) and CD16p5 (SEQ ID NO: 11)) were designed from the published human CD16-I sequence.
  • the primers on the line marked "Type II” (CD16pl (nucleotides 7-21 of SEQ ID
  • CD16-II (SEQ ID NO: 12) and CD16p6 (SEQ ID NO: 12)) were designed from the human CD16-II sequence.
  • CD16 isoform specific oligonucleotide primers for the 3 • end are shown as a single mismatch at position 829, G to A.
  • the melting temperature (T m ) of 3' PCR primers CD16-I and CD16-II are 53.9 and 46.3°C, respectively.
  • Panel B shows the result of restriction analysis of CD16 clones carried out using Endonuclease Dral.
  • the banding pattern for CD16-I and CD16-II are visualised; shown on the left panel are type I clones from PCR amplification using primer pair CD16pl and CD16p5, whereas the right panel shows type II clones from PCR amplification using primer pair CD16pl and CD16p6.
  • Figure 3 is a comparison of the CD16-II variants of the invention in nucleic acid sequence.
  • the first four sequences (SEQ ID NO: 12, 13, 14, and 15, respectively) are those coding for the four variants of the present invention, whereas the last is that already known and reported in Ravetch et al., J. EX . Med.. 170, pp. 481-7, 1989 (SEQ ID NO: 16) .
  • conserveed nucleotides are indicated by dashed lines, whereas changed ones are spelled in lower case alphabet.
  • Figure 4 shows the restriction map of plasmid pcDNAI/neo-sCD16-II, useful as expression vector for CD16-II variants in CHO cells, as well as the nucleotide and amino acid sequences of the coding portion thereof (SEQ ID NOS: 17 and 18) .
  • Figure 5 shows the restriction map of plasmid pETll(Swal) -CD16-II, useful as expression vector for CD16-II variants in E . coli as well as the nucleotide and amino acid sequences of the coding portion thereof (SEQ ID NOS: 19 and 20) .
  • Human lung polyA + RNA was purchased from Clontech.
  • Moloney Murine Leukaemia Virus RNase H " Reverse transcriptase (M-MLV H' RT) was purchased from BRL Life Technologies, Inc. VentTM DNA polymerase, restriction endonuclease ⁇ , and modifying enzymes were obtained from New England Biolabs. Sequenase Version 2.0 was purchased form US Biochemicals.
  • the plasmid used for subcloning, pBluescript+SK was purchased from Stratagene and used according to the manufacturer's recommendations.
  • CD16pl ATGTGGCAGCTGCTC (nucleotides 7-21 of SEQ ID NO: 17) as 5» PCR primer for both type I and type II; 2) CD16p5 and CD16p6: CTGCTGCCACTGCTC (SEQ ID NO:21) and CTGCTGCTACTGCTC (SEQ ID NO:22) as 3' PCR primers for type I and type II, respectively.
  • CD16p5 and CD16p6 CTGCTGCCACTGCTC (SEQ ID NO:21) and CTGCTGCTACTGCTC (SEQ ID NO:22) as 3' PCR primers for type I and type II, respectively.
  • These primers were designed to amplify each isoform of CD16 specifically under a given annealing temperature, i.e., 53.9°C for type I whereas 46.3°C for type-II (Fig. 2) .
  • RNA prepared from human lung tissue was used as a template for first strand cDNA synthesis.
  • a 50 ⁇ l reaction mixture was set up containing 2 ⁇ Poly-A+ RNA, 2.5 ⁇ g oligo -dT primer, 5.00 mM dNTPs, 50 mM Tris-HCl, pH 8.8, 75 mM KC1, 10 mM Dithiothreitol, 3 mM MgCl 2 , and 100 units M-MLV H_ RT.
  • 5 ml of 500 ml mM EDTA was added to the mixture.
  • the resultant mixture was extracted with an equal volume of Phenol/Chloroform/IAA (25:24:1) and precipitated with 3 volume of ethanol.
  • the precipitated reaction was resuspended in 10 ⁇ l of TE, and 1 ml was used for PCR amplification.
  • PCR amplifications were performed in 100 ml reaction mixture containing 200 ⁇ M of dATP, dCTP, dGTP, dTTP, 10 mM KC1, 20 mM Tris-HCl, pH 8.8, 10 mm (NH 4 ) 2 S0 4 , 2 mM MgS0 4 , 0.1% Triton X-100, 1 ⁇ l of ⁇ l (above) cDNA, and 4 units of VentTM.
  • Thermocycles were programmed as follows: 99°C, 10-minute incubation followed by 25 cycles of 94°C, 45 seconds; 54°C for type I or 46°C for type II, 1 minute; and 75°C, 1 minute, using GeneAmp PCR System 9600 (Perkin Elmer) . After agarose gel electrophoresis, resulting PCR products were extracted with phenol/chloroform, precipitated with ethanol, and digested with Ba HI to yield compatible restriction ends for subcloning into pBluescript+SK or further characterization.
  • CD16-I and -II were amplified specifically using RT-PCR.
  • the sequence comparison of CD16-I and CD16-II shows they are 98% identical.
  • isoform-specific oligonucleotide primers were designed and used to direct PCR amplifications under specific conditions, using the cDNA generated from human lung tissue mRNA.
  • the isoform-specific oligonucleotide primers for type I and II were chosen from the 3 '-untranslated region of the genes, nucleotides 822 to 836, where a single mismatch was found at nucleotide 829 (G for type-I whereas A for type-II, see Fig. 2, Panel A) .
  • Fourteen clones, picked randomly, were identified to be type I and type II by an endonuclease Dral digestion (Fig. 2, Panel B) .
  • CD16-I and -II were high sequence-identity of CD16-I and -II that led to the cloning strategy of using isoform-specific oligonucleotide primers for specific isoform isolation. Due to a 98% identity in nucleotide sequence between CD16-I and -II that led to the high sequence-identity of CD16-I and -II that led to the cloning strategy of using isoform-specific oligonucleotide primers for specific isoform isolation. Due to a 98% identity in nucleotide sequence between CD16-I and
  • CD16-II isoform-specific oligonucleotide primers 15(mers) were designed and used to direct PCR amplifications under specific conditions (primer-template annealing temperature 54°C and 46°C for type-I and type-II, respectively) .
  • These annealing condition can stabilise the perfect match of CD16p5 to type I cDNA template at 54°C, and that of CD16p6 to type II cDNA template at a lower annealing condition, 46°C.
  • annealing condition can stabilise the perfect match of CD16p5 to type I cDNA template at 54°C, and that of CD16p6 to type II cDNA template at a lower annealing condition, 46°C.
  • CD16-II In addition to polymorphic variants of CD16-I, a similar type of sequence variation was found in CD16-II (see Fig 3 for nucleic acid and Fig 1 for amino acid sequences) . Full length nucleotide sequence analyses were carried out and confirmed that cDNA clones for type-I contain a stop codon at 234 whereas those for type-II bear a codon for Arg at 234 and a stop codon at 255. In Fig 3, twenty-five nucleotide changes were observed. Of the 25 mismatches, 17 were found to cause codon changes (see Fig 3 and Fig 1) . The remaining 8 were fond to be silent mutations.
  • Trpl3l Gln-Asn-Gly- Lys 143-146 (residues 143-146 of SEQ ID NOS:6-9), Arg-Lys-Tyr 148-150, and Glyl68, remain unchanged.
  • glycine at position 147 located between two important motifs Gln-Asn- Gly-Lys 143-146 (residues 143-146 of SEQ ID NOS:6-9) and Arg- Lys-Tyr 148-150 was found changed to an aspartic acid, a conserved change.
  • glycine 147 can be mutated to, at least, alanine without severely altering the IgG binding property.
  • CD16-II there was a mutation observed in the putative transmembrane domain, Val214 to Ala, a conserved change.
  • a motif Leu-Phe- Ala-Val-Asp-Thr-Gly-Leu (residues 218-225 of SEQ ID NOS:6-9) in the transmembrane domain was found identical to the previously reported sequence. And this amino acid motif was found completely conserved through human and mouse CD16 and human, mouse, and rat Fc ⁇ RIa.
  • oligonucleotide primer CD16pl4 is designed as GGGAATTCAAAAGAATGATGAGATGGT (SEQ ID NO:23). CD16pl4 is designed so that a TGA stop codon is inserted after the Phe codon (Phe#203 is characteristic for CD16-II) .
  • CD16pl4 were used to amplify the soluble form of CD16-II (see Figure 4) .
  • the exact C terminus of the naturally occurring soluble form in CD16-II is yet to be determined; however, by choosing this truncation the engineered form of soluble CD16-II will contain the extracellular portion of the molecule.
  • oligonucleotide primers for E. coli expression of SCD16-II, oligonucleotide primers, CD16-(SwaI) and CD16N233, are designed as TTTGGATCCAAGCTTAGTTTGTCTTCACAGAGAAATAGAGACCT (SEQ ID NO:24) and TTTATTTAAATGCGTACTGAAGATCTCCCAAAG (SEQ ID NO:25) , respectively.
  • CD16-(SwaI) and CD16N233 primers are designed so that in E . coli , amino acid sequence from #18 to #233 (see Figure 5) could be produced, which is the mature protein, also containing the transmembranal domain.
  • Methotrexate (MTX) amplification is used in CHO cell expression of CD16-II.
  • plasmid pcDNAI/ neo-sCD16-II Large scale DNA preparation of plasmid pcDNAI/ neo-sCD16-II (see Figure 4) is carried out using Qiagen column followed by ethanol precipitation and was used for stable transfection by cotransfecting with D vector (containing the DHFR gene) for MTX selection.
  • D vector containing the DHFR gene
  • CHO transfectants are pooled and fully amplified to 5 ⁇ M MTX.
  • the highest sCD16 producing pool is selected and cultured in MTX-free basal medium (JRH, Biosciences) or MTX-free low protein medium (SFM-II, Gibco) .
  • the culture medium is collected at 24, 48 or 72 hours and used for purification on IgG affinity chromatography.
  • SCD16-II is done using OD 280 , SDS-PAGE, ELISA, Western blotting, amino acid composition analysis and N-terminal sequencing.
  • E. coli expression of SCD16-II isopropylthio- ⁇ -galactoside (IPTG) induced BL21/DE3 cells are incubated in lysis buffer and the soluble material analyzed using SDS-PAGE and Western blotting with polyclonal anti-hCD16 antisera.
  • IPTG isopropylthio- ⁇ -galactoside
  • Soluble CD16-II expressed in E . coli is also confirmed using N-terminal sequencing.
  • Ser Leu lie Ser Ser Gin Ala Ser Ser Tyr Phe lie Asp Ala Ala Thr 65 70 75 80 Val Asp Asp Ser Gly Glu Tyr Arg Cys Gin Thr Asn Leu Ser Thr Leu 85 90 95
  • Ser Leu lie Ser Ser Gin Ala Ser Ser Tyr Phe lie Asp Ala Ala Thr 65 70 75 80
  • Ser Leu lie Ser Ser Gin Ala Ser Ser Tyr Phe lie Asp Ala Ala Thr 65 70 75 80
  • Ser Leu lie Ser Ser Gin Ala Ser Ser Tyr Phe lie Asp Ala Ala Thr 65 70 75 80
  • Ser Leu lie Ser Ser Gin Ala Ser Ser Tyr Phe lie Asp Ala Ala Thr 65 70 75 80
  • Ser Leu lie Ser Ser Gin Ala Ser Ser Tyr Phe lie Asp Ala Ala Thr 65 70 75 80
  • GAAGATCTCC CAAAGGCTGT GGTGTTCCTG GAGCCTCAAT GGTACAGGGT GCTCGAGAAG 120
  • GAAGATCTCC CAAAGGCTGT GGTGTTCCTG GAGCCTCAAT GGTACAGGGT GCTCGAGAAG 120
  • GAAGATCTCC CAAAGGCTGT GGTGTTCCTG GAGCCTCAAT GGTACAGTGT GCTCGAGAAG 120
  • GACAGTGTGA CTCTGAAGTG CCAGGGAGCC TACTCCCCTG AGGACAATTC CACACAATGG 180 TTTCACAAAG AGAACCTCAT CTCAAGCCAG GCCTCGAGCT ACTTCATTGA CGCTGCCACA 240
  • GAAGATCTCC CAAAGGCTGT GGTGTTCCTG GAGCCTCAAT GGTACAGGGT GCTCGAGAAG 120
  • GAAGATCTCC CAAAGGCTGT GGTGTTCCTG GAGCCTCAAT GGTACAGGGT GCTCGAGAAG 120
  • AAA GGC AGG AAG TAT TTT CAT CAT AAT TCT GAC TTC TAC ATT CCA
  • GCC ACA CTC AAA GAC AGC GGC TCC TAC TTC TGC AGG GGG CTT TTT GGG 480 Ala Thr Leu Lys Asp Ser Gly Ser Tyr Phe Cys Arg Gly Leu Phe Gly 145 150 155 160
  • AGT AAA AAT GTG TCT TCA GAG ACT GTG AAC ATC ACC ATC ACT CAA GGT 528 Ser Lys Asn Val Ser Ser Glu Thr Val Asn He Thr He Thr Gin Gly 165 170 175
  • AGG TGT CAC AGC TGG AAG AAC ACT GCT CTG CAT AAG GTC ACA TAT TTA 432 Arg Cys His Ser Trp Lys Asn Thr Ala Leu His Lys Val Thr Tyr Leu 345 350 355 CAG AAT GGC AAA GGC AGG AAG TAT TTT CAT CAT AAT TCT GAC TTC TAC 480 Gin Asn Gly Lys Gly Arg Lys Tyr Phe His His Asn Ser Asp Phe Tyr 360 365 370

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention décrit des variants de la protéine CD16-II humaine, des séquences d'ADN les codant, leur utilisation dans la thérapie et/ou le diagnostic d'affections auto-immunes et de maladies inflammatoires, ainsi que des compositions pharmaceutiques les contenant. Elle décrit également la liste des séquences pour ces nouveaux polypeptides.
PCT/IB1996/000590 1995-05-03 1996-05-03 Variants de cd16-ii WO1996034953A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP8533162A JPH11511649A (ja) 1995-05-03 1996-05-03 Ｃｄ１６−ｉｉ変異体
CA002219988A CA2219988C (fr) 1995-05-03 1996-05-03 Variants de cd16-ii
EP96916264A EP0954576A2 (fr) 1995-05-03 1996-05-03 Variants de cd16-ii
KR1019970707811A KR100464923B1 (ko) 1995-05-03 1996-05-03 씨디16-2변이체들
AU59083/96A AU697991B2 (en) 1995-05-03 1996-05-03 CD16-II variants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/433,123 1995-05-03
US08/433,123 US6444789B1 (en) 1995-05-03 1995-05-03 CD16-II variants

Publications (2)

Publication Number Publication Date
WO1996034953A2 true WO1996034953A2 (fr) 1996-11-07
WO1996034953A3 WO1996034953A3 (fr) 1996-12-05

Family

ID=23718939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1996/000590 WO1996034953A2 (fr) 1995-05-03 1996-05-03 Variants de cd16-ii

Country Status (7)

Country Link
US (2) US6444789B1 (fr)
EP (2) EP1734119A3 (fr)
JP (1) JPH11511649A (fr)
KR (1) KR100464923B1 (fr)
AU (1) AU697991B2 (fr)
CA (1) CA2219988C (fr)
WO (1) WO1996034953A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700100B2 (en) 2003-01-13 2010-04-20 Macrogenics, Inc. FcγRIIB fusion proteins and compositions thereof
WO2015041303A1 (fr) * 2013-09-18 2015-03-26 東ソー株式会社 PROTÉINE DE LIAISON À Fc, PROCÉDÉ DE PRODUCTION DE LADITE PROTÉINE, ET ADSORBANT D'ANTICORPS UTILISANT LADITE PROTÉINE, ET PROCÉDÉS DE PURIFICATION ET D'IDENTIFICATION D'ANTICORPS AU MOYEN DUDIT ADSORBANT
EP3048112A1 (fr) * 2013-09-18 2016-07-27 Tosoh Corporation PROTÉINE DE LIAISON À Fc, PROCÉDÉ DE PRODUCTION DE LADITE PROTÉINE, ET ADSORBANT D'ANTICORPS UTILISANT LADITE PROTÉINE, ET PROCÉDÉS DE PURIFICATION ET D'IDENTIFICATION D'ANTICORPS AU MOYEN DUDIT ADSORBANT
US10464989B2 (en) 2014-03-28 2019-11-05 Regents Of The University Of Minnesota Polypeptides, cells, and methods involving engineered CD16
US11603548B2 (en) 2017-10-27 2023-03-14 Tosoh Corporation Fc-binding protein exhibiting improved alkaline resistance, method for producing said protein, antibody adsorbent using said protein, and method for separating antibody using said antibody adsorbent

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001293723A1 (en) * 2000-09-09 2002-03-22 Degussa A.G. Nucleotide sequences coding for the dep33 gene
US7511121B2 (en) * 2001-03-09 2009-03-31 Arnason Barry G W Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors
US8163289B2 (en) * 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
WO2003035904A2 (fr) * 2001-10-19 2003-05-01 Centre Hospitalier Regional Et Universitaire De Tours Procedes et compositions pour evaluer la reponse a un traitement a base d'anticorps
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
EP1697520A2 (fr) * 2003-12-22 2006-09-06 Xencor, Inc. Polypeptides fc a nouveaux sites de liaison de ligands fc
WO2005092925A2 (fr) * 2004-03-24 2005-10-06 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
US20070231813A1 (en) * 2004-06-01 2007-10-04 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a Gebotype and Methods for Evaluating Treatment Response to Non-Depleting Antibodies
US20070190657A1 (en) * 2004-06-15 2007-08-16 Universite Francois Rabelais Methods of assessing susceptibility to drug-induced thrombocytopenia
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP2332985A3 (fr) 2004-11-12 2012-01-25 Xencor, Inc. Variants de Fc avec une liaison altérée à fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
WO2006076594A2 (fr) * 2005-01-12 2006-07-20 Xencor, Inc. Anticorps et proteines de fusion fc a immunogenicite modifiee
EP1931709B1 (fr) * 2005-10-03 2016-12-07 Xencor, Inc. Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées
CA2625998C (fr) 2005-10-06 2015-12-01 Xencor, Inc. Anticorps anti-cd30 optimises
WO2008022152A2 (fr) * 2006-08-14 2008-02-21 Xencor, Inc. Anticorps optimisés ciblant cd19
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
SI2235059T1 (sl) 2007-12-26 2015-06-30 Xencor, Inc. Fc variante s spremenjeno vezjo na fcrn
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
JP6507522B2 (ja) * 2013-09-27 2019-05-08 東ソー株式会社 改良Ｆｃ結合性タンパク質、当該タンパク質の製造方法および当該タンパク質を用いた抗体吸着剤
JP2015083558A (ja) * 2013-09-18 2015-04-30 東ソー株式会社 抗体吸着剤ならびにそれを用いた抗体の精製方法および識別方法
WO2015199154A1 (fr) * 2014-06-27 2015-12-30 東ソー株式会社 Protéine de liaison au récepteur fc améliorée, procédé de production de ladite protéine, anticorps adsorbant utilisant ladite protéine, et procédés de séparation d'anticorps au moyen dudit adsorbant
JP6699096B2 (ja) * 2014-06-27 2020-05-27 東ソー株式会社 改良Ｆｃ結合性タンパク質、当該タンパク質の製造方法および当該タンパク質を用いた抗体吸着剤
JP6451118B2 (ja) * 2014-07-17 2019-01-16 東ソー株式会社 抗体の分離方法
JP6451119B2 (ja) * 2014-07-17 2019-01-16 東ソー株式会社 抗体依存性細胞傷害活性の強さに基づき抗体を分離する方法
EP3162895B1 (fr) 2014-06-27 2020-11-25 Tosoh Corporation Protéine de liaison au récepteur fc améliorée, procédé de production de ladite protéine, anticorps adsorbant utilisant ladite protéine, et procédés de séparation d'anticorps au moyen dudit adsorbant
JP6476807B2 (ja) * 2014-12-09 2019-03-06 東ソー株式会社 抗体の効率的な分離方法
CN113862292A (zh) 2015-01-29 2021-12-31 明尼苏达大学董事会 嵌合抗原受体、组合物以及方法
JP6932923B2 (ja) * 2015-12-24 2021-09-08 東ソー株式会社 改良Ｆｃ結合性タンパク質、当該タンパク質の製造方法および当該タンパク質を用いた抗体吸着剤
KR20230047014A (ko) * 2021-09-29 2023-04-06 카오티에스 주식회사 신규한 재조합 Fc 수용체 및 이를 포함하는 세포

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343950A2 (fr) * 1988-05-27 1989-11-29 Schering Biotech Corporation Récepteur humain Fc(gamma)RIII

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702481B1 (fr) 1993-03-09 1995-04-28 Roussel Uclaf Nouveaux récepteurs Fc-gamma III humains solubles, leur procédé de préparation, les compositions pharmaceutiques les contenant, leur application comme médicaments et leur application diagnostique.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343950A2 (fr) * 1988-05-27 1989-11-29 Schering Biotech Corporation Récepteur humain Fc(gamma)RIII

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 86, no. 10 (suppl. 1), 1 - 5 December 1995, NEW YORK, NY, USA, page 718A XP002015158 S. LUO: "Reverse transcription-based polymerase chain reaction cloning of Fc-gamma-R-III type II variants: Indicating a polymorphism of human CD16-II." *
IMMUNOMETHODS, vol. 4, no. 1, 1994, SAN DIEGO, CA, USA, pages 25-34, XP000604919 P. CAPEL ET AL.: "Heterogeneity of human IgG Fc receptors." *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 86, no. 13, July 1989, WASHINGTON, DC, USA, pages 5079-5083, XP002015156 B. SCALLON ET AL.: "A human immunoglobulin G receptor exists in both polypeptide-anchored and phosphatidylinositol-glycan-anchored forms." cited in the application *
SCIENCE, vol. 246, no. 4937, 22 December 1989, WAHINGTON, DC, USA, pages 1611-1613, XP002015157 L. LANIER ET AL.: "Membrane anchoring of a human IgG Fc receptor (CD16) determined by a single amino acid." cited in the application *
See also references of EP0954576A2 *
THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 170, no. 2, 1 August 1989, NEW YORK, NY, USA, pages 481-497, XP000604942 J. RAVETCH ET AL.: "Alternative membrane forms of FcgammaRIII (CD16) on human natural killer cells and neutrophils." cited in the application *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700100B2 (en) 2003-01-13 2010-04-20 Macrogenics, Inc. FcγRIIB fusion proteins and compositions thereof
WO2015041303A1 (fr) * 2013-09-18 2015-03-26 東ソー株式会社 PROTÉINE DE LIAISON À Fc, PROCÉDÉ DE PRODUCTION DE LADITE PROTÉINE, ET ADSORBANT D'ANTICORPS UTILISANT LADITE PROTÉINE, ET PROCÉDÉS DE PURIFICATION ET D'IDENTIFICATION D'ANTICORPS AU MOYEN DUDIT ADSORBANT
EP3048112A1 (fr) * 2013-09-18 2016-07-27 Tosoh Corporation PROTÉINE DE LIAISON À Fc, PROCÉDÉ DE PRODUCTION DE LADITE PROTÉINE, ET ADSORBANT D'ANTICORPS UTILISANT LADITE PROTÉINE, ET PROCÉDÉS DE PURIFICATION ET D'IDENTIFICATION D'ANTICORPS AU MOYEN DUDIT ADSORBANT
EP3048112A4 (fr) * 2013-09-18 2017-07-26 Tosoh Corporation PROTÉINE DE LIAISON À Fc, PROCÉDÉ DE PRODUCTION DE LADITE PROTÉINE, ET ADSORBANT D'ANTICORPS UTILISANT LADITE PROTÉINE, ET PROCÉDÉS DE PURIFICATION ET D'IDENTIFICATION D'ANTICORPS AU MOYEN DUDIT ADSORBANT
US10611817B2 (en) 2013-09-18 2020-04-07 Tosoh Corporation Fc-binding protein, method for producing said protein, and antibody adsorbent using said protein, and methods for purifying and identifying antibody using said adsorbent
US10464989B2 (en) 2014-03-28 2019-11-05 Regents Of The University Of Minnesota Polypeptides, cells, and methods involving engineered CD16
US11370825B2 (en) 2014-03-28 2022-06-28 Regents Of The University Of Minnesota Polypeptides, cells, and methods involving engineered CD16
US11603548B2 (en) 2017-10-27 2023-03-14 Tosoh Corporation Fc-binding protein exhibiting improved alkaline resistance, method for producing said protein, antibody adsorbent using said protein, and method for separating antibody using said antibody adsorbent

Also Published As

Publication number Publication date
US5998166A (en) 1999-12-07
EP0954576A2 (fr) 1999-11-10
JPH11511649A (ja) 1999-10-12
WO1996034953A3 (fr) 1996-12-05
AU697991B2 (en) 1998-10-22
KR19990008285A (ko) 1999-01-25
KR100464923B1 (ko) 2005-06-13
EP1734119A3 (fr) 2012-12-05
EP1734119A2 (fr) 2006-12-20
CA2219988A1 (fr) 1996-11-07
US6444789B1 (en) 2002-09-03
AU5908396A (en) 1996-11-21
CA2219988C (fr) 2009-04-28

Similar Documents

Publication Publication Date Title
AU697991B2 (en) CD16-II variants
Bateson et al. γ‐Aminobutyric acidA receptor heterogeneity is increased by alternative splicing of a novel β‐subunit gene transcript
Ellis et al. Human trophoblast and the choriocarcinoma cell line BeWo express a truncated HLA Class I molecule.
Spies et al. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway
Koller et al. Cloning and complete sequence of an HLA-A2 gene: analysis of two HLA-A alleles at the nucleotide level.
Alonso et al. cDNA cloning and sequence of MAL, a hydrophobic protein associated with human T-cell differentiation.
van den Elsen et al. Isolation of cDNA clones encoding the 20K T3 glycoprotein of human T-cell receptor complex
JP4185070B2 (ja) Ｉｌ−１３受容体ポリペプチド
Zoorob et al. Organization of a functional chicken class II B gene
US6482925B1 (en) Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants
Scott et al. The nucleotide sequence and evolution of ovine MHC class II B genes: DQB and DRB
EP1243597B1 (fr) Récepteurs pour l'interleukine-12 humaine
EP0636177A1 (fr) ISOLATION, CARACTERISATION ET UTILISATION DE LA SOUS-UNITE HUMAINE $g(b) DU RECEPTEUR DE HAUTE AFFINITE POUR L'IMMUNOGLOBULINE E
Schiffenbauer et al. Complete sequence of the HLA DQ alpha and DQ beta cDNA from a DR5/DQw3 cell line.
EP0804576B1 (fr) Nouveaux recepteurs de l'hemopoietine
CA2073378A1 (fr) Proteine trkc
Koettnitz et al. Human interleukin‐4 receptor signaling requires sequences contained within two cytoplasmic regions
Darling et al. Molecular genetics of MIC2: a gene shared by the human X and Y chromosomes
WO1993016102A1 (fr) Cd26 humain et procedes d'utilisation
Mouro et al. Molecular characterization of the Rh-like locus and gene transcripts from the rhesus monkey (Macaca mulatta)
Yu et al. Identification of amino acids in HLA-DPw4bβ and-DR5β1 chains that are involved in antibody binding epitodes using site-directed mutagenesis and DNA-mediated gene transfer
CN1308346C (zh) 新型人磷脂酰乙醇胺结合蛋白，其编码序列及用途
Apoil et al. Sequences and evolution of mammalian RH gene transcripts and proteins
Davodeau et al. Characterization of a new functional TCR J delta segment in humans. Evidence for a marked conservation of J delta sequences between humans, mice, and sheep.
US6818393B1 (en) DNA sequences coding for the DR beta-chain locus of the human lymphocyte antigen complex and polypeptides, diagnostic typing processes and products related thereto

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2219988

Country of ref document: CA

Ref country code: CA

Ref document number: 2219988

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1996 533162

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019970707811

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1996916264

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970707811

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1996916264

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019970707811

Country of ref document: KR